JP4822654B2 - 血管疾患治療用ｈｍｇｂ１蛋白質インヒビタおよび／またはアンタゴニスト - Google Patents

血管疾患治療用ｈｍｇｂ１蛋白質インヒビタおよび／またはアンタゴニスト Download PDF

Info

Publication number
JP4822654B2
JP4822654B2 JP2002573044A JP2002573044A JP4822654B2 JP 4822654 B2 JP4822654 B2 JP 4822654B2 JP 2002573044 A JP2002573044 A JP 2002573044A JP 2002573044 A JP2002573044 A JP 2002573044A JP 4822654 B2 JP4822654 B2 JP 4822654B2
Authority
JP
Japan
Prior art keywords
hmgb1
hmg
box domain
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002573044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004523579A (ja
JP2004523579A5 (https=
Inventor
エ ビアンキ マルコ
ボナルディ ティチアーナ
スカッフィーディ パオラ
ムエッレール スザンネ
デグリーゼ ベルナルド
Original Assignee
バイオ３ リサーチ ソシエタ ア レスポンサビリタ リミタータ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオ３ リサーチ ソシエタ ア レスポンサビリタ リミタータ filed Critical バイオ３ リサーチ ソシエタ ア レスポンサビリタ リミタータ
Publication of JP2004523579A publication Critical patent/JP2004523579A/ja
Publication of JP2004523579A5 publication Critical patent/JP2004523579A5/ja
Application granted granted Critical
Publication of JP4822654B2 publication Critical patent/JP4822654B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002573044A 2001-03-16 2002-03-12 血管疾患治療用ｈｍｇｂ１蛋白質インヒビタおよび／またはアンタゴニスト Expired - Fee Related JP4822654B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2001MI000562A ITMI20010562A1 (it) 2001-03-16 2001-03-16 Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
ITMI2001A000562 2001-03-16
PCT/IT2002/000153 WO2002074337A1 (en) 2001-03-16 2002-03-12 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases

Publications (3)

Publication Number Publication Date
JP2004523579A JP2004523579A (ja) 2004-08-05
JP2004523579A5 JP2004523579A5 (https=) 2005-08-18
JP4822654B2 true JP4822654B2 (ja) 2011-11-24

Family

ID=11447291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002573044A Expired - Fee Related JP4822654B2 (ja) 2001-03-16 2002-03-12 血管疾患治療用ｈｍｇｂ１蛋白質インヒビタおよび／またはアンタゴニスト

Country Status (14)

Country Link
US (4) US7754217B2 (https=)
EP (1) EP1368060B1 (https=)
JP (1) JP4822654B2 (https=)
CN (2) CN101773669A (https=)
AT (1) ATE468137T1 (https=)
AU (1) AU2002247977C1 (https=)
CA (1) CA2439530C (https=)
DE (1) DE60236413D1 (https=)
DK (1) DK1368060T3 (https=)
ES (1) ES2346408T3 (https=)
IT (1) ITMI20010562A1 (https=)
MX (1) MXPA03008364A (https=)
PT (1) PT1368060E (https=)
WO (1) WO2002074337A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
EP1392844A4 (en) * 2001-05-15 2006-09-06 Long Island Jewish Res Inst USE OF HMG FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
AU2003228099A1 (en) 2002-07-03 2004-01-23 Centro Cardiologico Monzino S.P.A.-Irccs Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
EP1579221A2 (de) * 2003-01-03 2005-09-28 Alcedo Biotech GmbH Verwendungen von hmgb, hmgn, hmga proteinen
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
PL1768677T3 (pl) * 2004-07-02 2009-01-30 Creabilis Therapeutics Spa Kwasy nukleinowe do leczenia patologii związanych z HMGB-1
EP1768693A1 (en) 2004-07-20 2007-04-04 Provincia Italiana Della Congregazione Dei Figli Dell'Immacolata Concezione - Istituto Dermopatico Dell'Immacolata Use of hmgb1 for wound healing
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
NZ553809A (en) * 2004-09-03 2010-03-26 Creabilis Therapeutics Spa Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1
US7585504B2 (en) 2004-10-22 2009-09-08 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
ITRM20050032A1 (it) * 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
WO2007011606A2 (en) 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
EP1919979B2 (en) 2005-08-25 2017-03-29 Creabilis Therapeutics S.P.A. Polymer conjugates of k-252a and derivatives thereof
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
WO2007130725A2 (en) * 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
AU2007296843C1 (en) 2006-09-15 2012-08-16 Creabilis Therapeutics S.P.A. Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
WO2008099913A1 (ja) 2007-02-15 2008-08-21 Kumamoto University ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
ES2654542T3 (es) 2008-04-30 2018-02-14 Genomix Co., Ltd. Procedimiento de recolección de células funcionales in vivo con alta eficiencia
JP5660889B2 (ja) 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
US9278108B2 (en) 2009-07-16 2016-03-08 Nec Solution Innovators, Ltd. HMGB1 binding nucleic acid molecule and applications thereof
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
US11191786B2 (en) 2009-10-28 2021-12-07 StemRIM Inc. Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood
AU2011322482B2 (en) 2010-10-30 2017-03-23 Oxford University Innovation Limited Treatment for Dupuytren's disease
EP2703487B1 (en) 2011-04-26 2018-06-27 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) * 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
DK2913059T3 (en) 2012-10-25 2018-06-25 Genomix Co Ltd Hitherto UNKNOWN PROCEDURE FOR TREATMENT OF SPINE INJURY USING HMGB1 FRAGMENT
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
US9550825B2 (en) 2013-01-28 2017-01-24 Evec Inc. Humanized anti-HMGB1 antibody or antigen-binding fragment thereof
IL242807A0 (en) 2015-11-26 2016-04-21 Novamed Ltd Test facility
AU2016366515A1 (en) 2015-12-11 2018-06-21 Ruprecht-Karls-Universität Heidelberg Combined preparations of PKM2 modulators and HMGB1
US11969459B2 (en) 2017-01-27 2024-04-30 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
CA3084013A1 (en) 2017-12-01 2019-06-06 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
WO2019107530A1 (ja) 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
JP7455433B2 (ja) * 2020-04-22 2024-03-26 チュラーロンコーン ユニバーシティー Ｄｎａを回復する及びｄｎａ損傷を防止する組成物及び方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039121A1 (en) * 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
WO1998022138A1 (en) * 1996-11-22 1998-05-28 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5470307A (en) * 1994-03-16 1995-11-28 Lindall; Arnold W. Catheter system for controllably releasing a therapeutic agent at a remote tissue site
AU1832797A (en) 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6398808B1 (en) 1999-06-15 2002-06-04 Scimed Life Systems, Inc. Localized delivery of genetic information from biostable materials
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
EP1392844A4 (en) * 2001-05-15 2006-09-06 Long Island Jewish Res Inst USE OF HMG FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
EP1768693A1 (en) * 2004-07-20 2007-04-04 Provincia Italiana Della Congregazione Dei Figli Dell'Immacolata Concezione - Istituto Dermopatico Dell'Immacolata Use of hmgb1 for wound healing
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039121A1 (en) * 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
WO1998022138A1 (en) * 1996-11-22 1998-05-28 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes

Also Published As

Publication number Publication date
CN1537014A (zh) 2004-10-13
AU2002247977B8 (en) 2007-03-15
EP1368060B1 (en) 2010-05-19
HK1069316A1 (en) 2005-05-20
US8058239B2 (en) 2011-11-15
US20100172896A1 (en) 2010-07-08
AU2002247977C1 (en) 2008-09-18
WO2002074337A1 (en) 2002-09-26
AU2002247977A1 (en) 2002-10-03
WO2002074337A8 (en) 2003-08-28
DE60236413D1 (de) 2010-07-01
US20080171052A1 (en) 2008-07-17
CA2439530C (en) 2016-11-08
JP2004523579A (ja) 2004-08-05
US7754217B2 (en) 2010-07-13
CN1537014B (zh) 2012-04-25
ATE468137T1 (de) 2010-06-15
ES2346408T3 (es) 2010-10-15
MXPA03008364A (es) 2004-11-12
US20040136979A1 (en) 2004-07-15
EP1368060A1 (en) 2003-12-10
CA2439530A1 (en) 2002-09-26
AU2002247977A2 (en) 2004-02-26
DK1368060T3 (da) 2010-08-30
PT1368060E (pt) 2010-08-24
CN101773669A (zh) 2010-07-14
AU2002247977B2 (en) 2006-12-14
ITMI20010562A1 (it) 2002-09-16
US20100297107A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
JP4822654B2 (ja) 血管疾患治療用ｈｍｇｂ１蛋白質インヒビタおよび／またはアンタゴニスト
Degryse et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells
JP4819364B2 (ja) 線維細胞形成阻害の検出方法、ならびに線維細胞形成を増強する方法および化合物
Rodrigues-Diez et al. The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response
JP2002539174A (ja) 癌および血管新生関連の疾病の治療のためのｌｄｌ様受容体リガンドを使用する組成物および方法
Lipitsä et al. Complement C3 is expressed by mast cells in cutaneous vasculitis and is degraded by chymase
US20090214549A1 (en) Antigenic Epitopes Of Inteleukin-21, Related Antibodies And Their Use In Medical Field
Ambort et al. Specific processing of tenascin-C by the metalloprotease meprinβ neutralizes its inhibition of cell spreading
US7824868B2 (en) Formation of superfibronectin by BBK32 and uses therefor
Garnier et al. Factor XII protects neurons from apoptosis by epidermal and hepatocyte growth factor receptor‐dependent mechanisms
AU765126B2 (en) Invasion-inducing agents and invasion-inhibitors for use in wound healing and cancer
Lambert et al. The interaction of Tamm-Horsfall protein with the extracellular matrix
US20090220484A1 (en) Rage/Diaphanous Interaction and Related Compositions and Methods
HK1146703A (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
HK1069316B (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
US20210189368A1 (en) Recombinant fusion proteins for preventing or treating adhesions of tissues or organs
ES2362655T3 (es) Métodos y composiciones para suprimir la diferenciación de fibrocitos.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080731

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100223

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100323

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100426

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110816

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110906

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140916

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees